BeiGene’s Brukinsa outshines Janssen’s Imbruvica in comparison trial R&D, Therapeutics In a head-to-head comparison trial, BeiGene’s Brukinsa (zanubrutinib) bested Janssen’s Imbruvica (ibrutinib) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). Read more December 14, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/12/BioSpaceBeiGene12-14-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-12-14 11:00:502022-12-14 11:00:50BeiGene’s Brukinsa outshines Janssen’s Imbruvica in comparison trial
